Mary Kay Fenton, CFO of Cullinan Therapeutics ($CGEM), made one open market sale of company shares in the last year, totaling about $60,000. Her most recent sale occurred on February 20, 2026. This ranks her 10,197th among 11,678 insiders by sale value, well below the average of $8.6 million across 6.4 transactions per insider. She reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 20, 2026 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | S | Common Stock | 4398 | $13.62 | 126,380.0000 | 59,076,259 | 3.36% | 0.01% |
| Feb. 18, 2026 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | A | Common Stock | 68750 | $0.00 | 130,778.0000 | 59,076,259 | 110.84% | 0.12% |
| Feb. 18, 2026 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | A | Stock Option (Right to Buy) | 137500 | $0.00 | 137,500.0000 | 59,076,259 | 9999.99% | 0.23% |
| Dec. 31, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | A | Common Stock | 27 | $6.49 | 62,028.0000 | 59,076,259 | 0.04% | 0.00% |
| Feb. 19, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | A | Common Stock | 60000 | $0.00 | 60,000.0000 | 58,510,610 | 9999.99% | 0.10% |
| Feb. 19, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | A | Stock Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 58,510,610 | 9999.99% | 0.21% |
| April 29, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Fenton Mary Kay | Chief Financial Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 42,900,083 | 9999.99% | 0.47% |